Literature DB >> 26769715

Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases.

Michelle M Kim1, Hemant Parmar1, Yue Cao1, Susan J Knox1, Bryan Oronsky1, Jan Scicinski1, Theodore S Lawrence1, Christopher D Lao1.   

Abstract

Entities:  

Keywords:  brain metastases; melanoma; radioresistance; radiosensitizer; whole brain radiotherapy

Mesh：

Substances：

Year:  2016        PMID： 26769715      PMCID： PMC4767246          DOI： 10.1093/neuonc/nov317

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  3 in total

1.  Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.

Authors:  Tony Reid; Bryan Oronsky; Jan Scicinski; Curt L Scribner; Susan J Knox; Shoucheng Ning; Donna M Peehl; Ron Korn; Meaghan Stirn; Corey A Carter; Arnold Oronsky; Michael J Taylor; William L Fitch; Pedro Cabrales; Michelle M Kim; Howard A Burris; Christopher D Lao; Nacer E D Abrouk; Gary R Fanger; Jeffrey R Infante
Journal:  Lancet Oncol       Date:  2015-08-19       Impact factor: 41.316

2.  Prognostic factors for outcomes after whole-brain irradiation of brain metastases from relatively radioresistant tumors: a retrospective analysis.

Authors:  Thekla Meyners; Christine Heisterkamp; Jan-Dirk Kueter; Theo Veninga; Lukas J A Stalpers; Steven E Schild; Dirk Rades
Journal:  BMC Cancer       Date:  2010-10-26       Impact factor: 4.430

3.  Cerebral melanoma metastases: a critical review on diagnostic methods and therapeutic options.

Authors:  Carlos R Goulart; Tobias Alecio Mattei; Ricardo Ramina
Journal:  ISRN Surg       Date:  2011-05-25
  3 in total
  6 in total

1.  RRx-001 protects against cisplatin-induced toxicities.

Authors:  Bryan Oronsky; Tony R Reid; Christopher Larson; Corey A Carter; Christina E Brzezniak; Arnold Oronsky; Pedro Cabrales
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-17       Impact factor: 4.553

2.  RRx-001 Radioprotection: Enhancement of Survival and Hematopoietic Recovery in Gamma-Irradiated Mice.

Authors:  Kimberly J Jurgensen; William K J Skinner; Bryan Oronsky; Nacer D Abrouk; Andrew E Graff; Reid D Landes; William E Culp; Thomas A Summers; Lynnette H Cary
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

3.  RRx-001 Increases Erythrocyte Preferential Adhesion to the Tumor Vasculature.

Authors:  Vinay P Jani; Robert Asaro; Bryan Oronsky; Pedro Cabrales
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

4.  Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma.

Authors:  Min-Jung Lee; Yusuke Tomita; Akira Yuno; Sunmin Lee; Nacer E Abrouk; Bryan Oronsky; Scott Caroen; Jane B Trepel
Journal:  Expert Opin Investig Drugs       Date:  2021-01-11       Impact factor: 6.498

5.  A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

Authors:  Bryan Oronsky; Scott Caroen; Karen Zeman; Mary Quinn; Christina Brzezniak; Jan Scicinski; Pedro Cabrales; Tony R Reid; Jane B Trepel; Nacer D Abrouk; Christopher Larson; Arnold Oronsky; Harry E Lybeck; Regina M Day; Corey A Carter
Journal:  Clin Med Insights Oncol       Date:  2016-11-06

6.  Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors.

Authors:  Natarajan Raghunand; Jan Scicinski; Gerald P Guntle; Bhumasamudram Jagadish; Eugene A Mash; Elizabeth Bruckheimer; Bryan Oronsky; Ronald L Korn
Journal:  Oncotarget       Date:  2017-06-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.